Sacituzumab govitecan improves OS in heavily pretreated patients

Affiliations

Comment

Peter Sidaway. Nat Rev Clin Oncol. 2023 Nov.

. 2023 Nov;20(11):734.

doi: 10.1038/s41571-023-00818-2.

No abstract available

Comment on

Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial.
Rugo HS, Bardia A, Marmé F, Cortés J, Schmid P, Loirat D, Trédan O, Ciruelos E, Dalenc F, Gómez Pardo P, Jhaveri KL, Delaney R, Valdez T, Wang H, Motwani M, Yoon OK, Verret W, Tolaney SM. Rugo HS, et al. Lancet. 2023 Oct 21;402(10411):1423-1433. doi: 10.1016/S0140-6736(23)01245-X. Epub 2023 Aug 23. Lancet. 2023. PMID: 37633306 Clinical Trial.

1. Rugo, H. S. et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet https://doi.org/10.1016/S0140-6736(23)01245-X (2023) - DOI - PubMed